| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 07/23/2002 | US6423547 Non-covalent bioconjugates useful for diagnosis and therapy |
| 07/23/2002 | US6423539 Enhancing immunology response |
| 07/23/2002 | US6423527 Sphingosine-1-phosphate lyase polypeptides, polynucleotides and modulating agents and methods of use therefor |
| 07/23/2002 | US6423521 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |
| 07/23/2002 | US6423519 Contacting fungal cell with compound which inhibits prenyltransferase activity of cell, including permease tag which facilitates permease-mediated transport of compound into cell, inhibiting growth thereof |
| 07/23/2002 | US6423508 Polynucleotide sequences of human EDG-1c |
| 07/23/2002 | US6423349 Compositions comprising glutamine in combination with other nutrients, including n-acetyl-cysteine and vitamins a, c, e are disclosed. |
| 07/23/2002 | US6423327 Treating wrinkles of skin with adenosine |
| 07/23/2002 | US6423319 Methods for treating muscle injuries |
| 07/23/2002 | US6423311 Mammals grafting cells with radiation |
| 07/23/2002 | CA2369183A1 Means and methods for treatment evaluation |
| 07/23/2002 | CA2368791A1 Medicament for the protection against thrombotic diseases |
| 07/23/2002 | CA2215317C Reduction of adhesions using controlled delivery of active oxygen inhibitors |
| 07/23/2002 | CA2101556C Growth factor containing matrix for the treatment of cartilage lesions |
| 07/23/2002 | CA2040865C Method for preventing, stabilizing or causing regression of atherosclerosis employing a combination of a cholesterol lowering drug and an ace inhibitor |
| 07/22/2002 | CA2368485A1 Combination treatment for depression |
| 07/18/2002 | WO2002056027A2 Regulation of neutral development by daedalos |
| 07/18/2002 | WO2002056022A2 Diagnostics, drug screening and treatment for cancer |
| 07/18/2002 | WO2002055721A2 Modular transfection systems based on nucleoprotein filaments |
| 07/18/2002 | WO2002055720A2 Materials and methods relating to protein aggregation in neurodegenerative disease |
| 07/18/2002 | WO2002055698A2 Transcriptional mediators of blood vessel development and endothelial differentiation |
| 07/18/2002 | WO2002055691A1 Gene encoding aip-1/flash promoter and use thereof |
| 07/18/2002 | WO2002055688A2 Histone deacetylase inhibitors in diagnosis and treatment of thyroid neoplasms |
| 07/18/2002 | WO2002055663A2 Srebp pathway modulation through targeting hisrs |
| 07/18/2002 | WO2002055547A2 Sfrp and peptide motifs that interact with sfrp and methods of their use |
| 07/18/2002 | WO2002055544A2 Fibrin binding polypeptides useful inter alia in medical imaging processes |
| 07/18/2002 | WO2002055533A2 Methods of using imxp-888 and imxp-888 antagonists |
| 07/18/2002 | WO2002055524A1 THIENO(3,2-d)PYRIMIDINES AND FURANO(3,2-d)PYRIMIDINES AND THEIR USE AS PURINERGIC RECEPTOR ANTAGONISTS |
| 07/18/2002 | WO2002055521A1 Purine derivatives as purinergic receptor antagonists |
| 07/18/2002 | WO2002055517A2 4-(hetero)aryl substituted indolinones |
| 07/18/2002 | WO2002055515A1 Chemical derivatives and their use as anti-telomerase agent |
| 07/18/2002 | WO2002055502A1 Pyridine derivatives useful as cyclooxygenase inhibitor |
| 07/18/2002 | WO2002055498A1 Pharmaceutically active piperidine derivatives |
| 07/18/2002 | WO2002055152A2 Composition for inducing islet neogenesis, containing gastrin/cck receptor ligands and egf receptor ligands |
| 07/18/2002 | WO2002055136A2 Intrasvascular drug delivery device and use therefor |
| 07/18/2002 | WO2002055107A1 Topical anesthesia compositions |
| 07/18/2002 | WO2002055106A2 Combination therapy using receptor tyrosine kinase inhibitors and angiogenesis inhibitors |
| 07/18/2002 | WO2002055100A2 Method and composition for inhibition of tumor growth and enhancing an immune response |
| 07/18/2002 | WO2002055098A2 Latency associated peptide for providing latency to pharmaceutically active proteins |
| 07/18/2002 | WO2002055093A2 Activated charcoal based composition and method for reducing hangover symptoms associated with the consumption of alcohol containing beverages |
| 07/18/2002 | WO2002055087A1 Dihydro-triterpenes in the treatment of viral infections, cardiovascular disease, inflammation, hypersensitivity or pain |
| 07/18/2002 | WO2002055086A2 Hormone replacement therapy method and its administration form |
| 07/18/2002 | WO2002055085A2 Use of an adenosine a3 receptor agonist for inhibition of viral replication |
| 07/18/2002 | WO2002055083A1 TRIAZOLO[4,5-d] PYRIMIDINE DERIVATIVES AND THEIR USE AS PURINERGIC RECEPTOR ANTAGONISTS |
| 07/18/2002 | WO2002055072A1 Regulation of lipids and/or bone density and compositions therefor |
| 07/18/2002 | WO2002055065A2 Use of an ltb4 antagonist for the treatment and/or prevention of diseases caused by increased expression of mucin genes |
| 07/18/2002 | WO2002055064A2 Mucopolysaccharidosis therapies |
| 07/18/2002 | WO2002055024A2 Therapeutic modulation of the tumor inflammatory response |
| 07/18/2002 | WO2002055022A2 Active metabolite of antifungal compound |
| 07/18/2002 | WO2002055009A1 Spaced drug delivery system |
| 07/18/2002 | WO2002054997A1 Devices for local and systemic delivery of active substances and methods of manufacturing thereof |
| 07/18/2002 | WO2002054872A1 Liquid antimicrobial compositions |
| 07/18/2002 | WO2002039978A8 Supplement to be enterally administered for parenteral nutrition or partial enteral/oral nutrition of the critically ill, the chronically ill and people with malnutrition |
| 07/18/2002 | WO2002034280A3 Use of vanilloid 4 receptor and antagonists or agonists thereof for treating diseases associated with pain |
| 07/18/2002 | WO2002031025A3 Biodegradable poly(beta-amino esters) and uses thereof |
| 07/18/2002 | WO2002028414B1 Compositions and methods for wt1 specific immunotherapy |
| 07/18/2002 | WO2002022159A8 Thionin as an antineoplastic and immunostimulant |
| 07/18/2002 | WO2002012224A3 Bicyclic compounds as h3 receptor ligands |
| 07/18/2002 | WO2002011704A3 Use of aryl-substituted 1,1-diphosphonates for the treatment of bone diseases |
| 07/18/2002 | WO2002009713A3 Selective pde 2 inhibitors, used as medicaments for improving cognition |
| 07/18/2002 | WO2002008198A3 Novel imidazolidinones as ns3-serine protease inhibitors of hepatitis c virus |
| 07/18/2002 | WO2002006316A3 Alpha-msh related compounds and methods of use |
| 07/18/2002 | WO2002002633A3 Transporters and ion channels |
| 07/18/2002 | WO2002002143A3 Enhancement of antibody-cytokine fusion protein mediated immune responses by combined treatment with immunocytokine uptake enhancing agents |
| 07/18/2002 | WO2001094951A3 Inhibitors of c-reactive protein induced inflammation |
| 07/18/2002 | WO2001094391A3 Intracellular signaling proteins |
| 07/18/2002 | WO2001090328A3 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |
| 07/18/2002 | WO2001089499A3 Use of pyridinylimidazole carbamate derivate for the manufacture of a medicament for the treatment of cancer |
| 07/18/2002 | WO2001087980A3 Isolated human g-protein coupled receptors, nucleic acid molecules encoding human gpcr proteins, and uses thereof |
| 07/18/2002 | WO2001085790A3 Mammalian cytokine receptor subunit proteins, related reagents and methods |
| 07/18/2002 | WO2001084149A3 Diagnostics and therapeutics for macular degeneration-related disorders |
| 07/18/2002 | WO2001082932A3 Methods and compositions for enhancing cellular function through protection of tissue components |
| 07/18/2002 | WO2001082920A3 Treatment of congestive heart failure with a composition comprising a diuretic agent and a vasopressin antagonist |
| 07/18/2002 | WO2001081590A3 Protein phosphatases |
| 07/18/2002 | WO2001079468A3 Drug metabolizing enzymes |
| 07/18/2002 | WO2001079282A3 Molecules associated with human reproduction |
| 07/18/2002 | WO2001074340A3 Drug combination for the treatment of headache comprising mirtazapine and paracetamol or a non-steroidal anti-inflammatory drug |
| 07/18/2002 | WO2001072685A3 Polyamine analogues as cytotoxic agents |
| 07/18/2002 | WO2001068705A3 Il-17 receptor like molecules and uses thereof |
| 07/18/2002 | WO2001068065A9 Compositions comprising blockers of l-dopa renal cell transfer for the treatment of parkinson's disease |
| 07/18/2002 | WO2001062920A3 Compositions and methods for diagnosis and therapy of malignant mesothelioma |
| 07/18/2002 | WO2001060400B1 Use of inhibitors of caspase-3 or caspase-activated desoxyribonuclease (cad) for treating cardiac disease |
| 07/18/2002 | WO2001056547A3 Preparation of aqueous clear solution dosage forms with bile acids |
| 07/18/2002 | WO2001044514A3 Methods and compositions for identifying morphogenic protein analogs using morphogenic protein responsive inhibitory elements |
| 07/18/2002 | WO2001008717A9 Controlled release implantable devices |
| 07/18/2002 | WO2001008682A3 Use of flupirtine for alleviating pain caused by degenerative joint diseases in dogs and cats |
| 07/18/2002 | WO2001005834A9 Human tumor necrosis factor receptors tr13 and tr14 |
| 07/18/2002 | WO2000078972A9 Regulation with binding cassette transporter protein abc1 |
| 07/18/2002 | US20020095258 System and methods for optimized drug delivery and progression of diseased and normal cells |
| 07/18/2002 | US20020095000 Treatment of dry eye syndrome |
| 07/18/2002 | US20020094998 Methods and compositions for treatment of ocular neovascularization and neural injury |
| 07/18/2002 | US20020094996 Compositions and methods for lowering plasma lipoprotein(a) and risk factors of cardiovascular diseases |
| 07/18/2002 | US20020094992 Administering growth hormone secretagogue which is 2-amino-N-(2-(3a-(R)-benzyl-2-methyl-3-oxo-2,3,3a, 4,6,7-hexahydro-pyrazolo(4,3-c)pyridin-5-yl)1-(R)-benzyloxymet hyl-2-oxo-ethyl)-isobutyramide, salt or prodrug |
| 07/18/2002 | US20020094991 Methods and compositions for treating microtubule-mediated viral infections and lesions |
| 07/18/2002 | US20020094986 Combination treatment for depression, anxiety and psychosis |
| 07/18/2002 | US20020094985 Differential delivery of nitric oxide |
| 07/18/2002 | US20020094979 Use of 5HT-6 antagonists |
| 07/18/2002 | US20020094975 Effective to block sensory and motor functions of a nerve(s) at the site of administration; treating all categories of pain - acute or chronic, local or general; interfering with the nerve(s) propagating such pain |
| 07/18/2002 | US20020094960 Specifically unipolar depression, treatment-refractory depression, resistant depression, anxious depression and dysthymia; 2-sulfamatomethyltetrahydropyrans and sulfamato-methylcyclohexanes, e.g. topiramate |
| 07/18/2002 | US20020094955 Plasminogen-like polynucleotides, polypeptides, and antibodies |